Last reviewed · How we verify

NCT05223439

Balance and Gait on Neuropathic Pain Due to Lumbar Disc Degeneration

Completed Last updated 2 April 2024
What this trial tests

trial in Neuropathic Pain in 42 participants. Completed in 1 February 2024.

Timeline
5 January 2022
Primary endpoint
1 August 2023
1 February 2024

Quick facts

Lead sponsorHacettepe University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment42
Start date5 January 2022
Primary completion1 August 2023
Estimated completion1 February 2024
Sites2 locations across Turkey (Türkiye)

Conditions studied

Sponsor

Hacettepe University

Who can join

Adults 40 to 70, any sex, with Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic lumbar neuropathic pain, characterized by pain, numbness, tingling and muscle weakness in the lower extremities, is one of the most common neuropathic pain syndromes. It is expected that balance and gait disturbances will occur as a result of motor and sensory problems in patients with neuropathic pain due to lumbar disc degeneration. However, as far as the investigators know, there is no study in the literature describing the effects of neuropathic pain due to lumbar disc degeneration on balance and gait. Therefore, the aim of our study; To examine the effects of neuropathic pain due to lumbar disc degeneration on balance and gait.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neuropathic Pain

Currently open trials in the same condition.

Other Hacettepe University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05223439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing